Literature DB >> 31564024

Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector.

N C Parra1, R Mansilla1, G Aedo1, N S Vispo2, E E González-Horta3, I González-Chavarría3, C Castillo3, F Camacho1, O Sánchez4.   

Abstract

The vascular endothelial growth factor (VEGF) is an essential factor to pathologic angiogenesis. Disruption of VEGF/VEGF receptor interaction in cancer patients inhibits the development of new and pre-existing tumor blood vessels. Consequently, VEGF becomes an important therapeutic target for handling solid tumors. In this work, human VEGF was produced in the culture supernatant of SiHa cells transduced with a replication-defective adenoviral vector (pAdhVEGF121) encoding this molecule. The 35 kDa VEGF121 homodimer was obtained from clarified culture media as a glycosylated protein. VEGF121 expression levels were strictly dependent on the adenoviral viral load used. VEGF121 was produced with purity over 98% after a single step chromatography by immobilized metal affinity chromatography. Additionally, VEGF121 binds Bevacizumab antibody with a KD of 7 nM. Biological characterization by mitogenic assay in HUVEC and ECV-304 cells showed that VEGF121 stimulates cell proliferation in a dose-dependent manner in both cells. Finally, the neovascularization activity of VEGF121 was demonstrated by vascular permeability assays in matrigel plug-bearing mice, showing significantly increased vasculature leakage after treatment with VEGF121. Consequently, transduction of SiHa cells with adenovirus is a suitable alternative for manufacture heterologous proteins of therapeutic interest.

Entities:  

Keywords:  Adenoviral vector; ECV-304 cells; HUVEC; VEGF121; Vascular permeability

Mesh:

Substances:

Year:  2019        PMID: 31564024     DOI: 10.1007/s10930-019-09867-y

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  76 in total

Review 1.  Adenovirus vectors for gene delivery.

Authors:  K Benihoud; P Yeh; M Perricaudet
Journal:  Curr Opin Biotechnol       Date:  1999-10       Impact factor: 9.740

Review 2.  Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.

Authors:  E Grabenhorst; P Schlenke; S Pohl; M Nimtz; H S Conradt
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

3.  Subunit influenza vaccine candidate based on CD154 fused to HAH5 increases the antibody titers and cellular immune response in chickens.

Authors:  Alaín González Pose; Julia Noda Gómez; Alina Venereo Sánchez; Armando Vega Redondo; Elsa Rodríguez Rodríguez; Raquel Montesino Seguí; Ernesto Manuel González Ramos; María Pilar Rodríguez Moltó; Elaine Santana Rodríguez; Liliam Rios Cordero; Alina Rodríguez Mallón; Carlos Borroto Nordelo
Journal:  Vet Microbiol       Date:  2011-05-25       Impact factor: 3.293

4.  Functionally active VEGF fusion proteins.

Authors:  M V Backer; J M Backer
Journal:  Protein Expr Purif       Date:  2001-10       Impact factor: 1.650

5.  Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity.

Authors:  D Peretz; H Gitay-Goren; M Safran; N Kimmel; D Gospodarowicz; G Neufeld
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

6.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Authors:  K A Houck; D W Leung; A M Rowland; J Winer; N Ferrara
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

Review 7.  Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia.

Authors:  Trevor D Crafts; Amanda R Jensen; Ethan C Blocher-Smith; Troy A Markel
Journal:  Cytokine       Date:  2014-09-18       Impact factor: 3.861

8.  The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability.

Authors:  S Kondo; T Matsumoto; Y Yokoyama; I Ohmori; H Suzuki
Journal:  Biochim Biophys Acta       Date:  1995-02-23

Review 9.  Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis.

Authors:  Judith C Sluimer; Mat J Daemen
Journal:  J Pathol       Date:  2009-05       Impact factor: 7.996

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.